Literature DB >> 9716045

Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia.

P Cohen, D M Peehl, R Rosenfeld.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9716045      PMCID： PMC2063105          DOI： 10.1038/bjc.1998.535

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  9 in total

1.  Correction and withdrawal of conclusion--a child with phenotypic Laron dwarfism and normal somatomedin levels.

Authors:  C Pintor; S Loche; S G Cella; E E Müller; G Baumann
Journal:  N Engl J Med       Date:  1990-11-22       Impact factor: 91.245

2.  A child with phenotypic Laron dwarfism and normal somatomedin levels.

Authors:  Z Laron; A Silbergeld
Journal:  N Engl J Med       Date:  1989-06-22       Impact factor: 91.245

3.  A child with phenotypic Laron dwarfism and normal somatomedin levels.

Authors:  C Pintor; S Loche; S G Cella; E E Müller; G Baumann
Journal:  N Engl J Med       Date:  1989-02-09       Impact factor: 91.245

4.  Comparison of acid ethanol extraction and acid gel filtration prior to IGF-I and IGF-II radioimmunoassays: improvement of determinations in acid ethanol extracts by the use of truncated IGF-I as radioligand.

Authors:  P Bang; U Eriksson; V Sara; I L Wivall; K Hall
Journal:  Acta Endocrinol (Copenh)       Date:  1991-06

5.  Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.

Authors:  P J Ho; R C Baxter
Journal:  Clin Endocrinol (Oxf)       Date:  1997-03       Impact factor: 3.478

6.  Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen.

Authors:  H Kanety; Y Madjar; Y Dagan; J Levi; M Z Papa; C Pariente; B Goldwasser; A Karasik
Journal:  J Clin Endocrinol Metab       Date:  1993-07       Impact factor: 5.958

7.  Comparison of the effectiveness of various procedures for reducing or eliminating insulin-like growth factor-binding protein interference with insulin-like growth factor-I radioimmunoassays on porcine sera.

Authors:  R S Frey; M R Hathaway; W R Dayton
Journal:  J Endocrinol       Date:  1994-02       Impact factor: 4.286

Review 8.  Serum somatomedin binding proteins: physiologic significance and interference in radioligand assay.

Authors:  W H Daughaday; M Kapadia; I Mariz
Journal:  J Lab Clin Med       Date:  1987-03

9.  Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia.

Authors:  C S Mantzoros; A Tzonou; L B Signorello; M Stampfer; D Trichopoulos; H O Adami
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640
  9 in total
  3 in total

1.  A system for studying epithelial-stromal interactions reveals distinct inductive abilities of stromal cells from benign prostatic hyperplasia and prostate cancer.

Authors:  Wendy W Barclay; Ralph D Woodruff; M Craig Hall; Scott D Cramer
Journal:  Endocrinology       Date:  2004-10-07       Impact factor: 4.736

2.  Association of prostate-specific antigen promoter genotype with clinical and histopathologic features of prostate cancer.

Authors:  Scott D Cramer; Jielin Sun; S Lilly Zheng; Jianfeng Xu; Donna M Peehl
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-09       Impact factor: 4.254

3.  Association of reported prostate cancer risk alleles with PSA levels among men without a diagnosis of prostate cancer.

Authors:  Fredrik Wiklund; S Lilly Zheng; Jielin Sun; Hans-Olov Adami; Hans Lilja; Fang-Chi Hsu; Pär Stattin; Jan Adolfsson; Scott D Cramer; David Duggan; John D Carpten; Bao-Li Chang; William B Isaacs; Henrik Grönberg; Jianfeng Xu
Journal:  Prostate       Date:  2009-03-01       Impact factor: 4.104
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.